fbpx
Log in
Log in
Life Sciences Premium article

SOPHiA GENETICS Stock – A Play on Data Driven Medicine

Cancer Genomics Genomics Precision Medicine
July 26. 2021. 5 mins read

When artificial intelligence (AI) algorithms are able to predict how proteins fold based on amino acid sequences, it makes one wonder why it’s taking so long to move from spray-and-pray medicine to data-driven medicine. Today’s AI algorithms are certainly sophisticated enough, and there’s plenty of delicious big data to be found. The problem lies in aggregating the data from all the disparate silos where it currently lives. One company looking to start mankind down the path toward data-driven precision medicine is SOPHiA GENETICS (SOPH).

About SOPHiA GENETICS Stock

Click for company website

We first came across SOPHiA GENETICS several years back in a piece on The Top-10 Artificial Intelligence Startups in Switzerland, and then again in our piece on

Sign up to our newsletter to get more of our great research delivered straight to your inbox!

Nanalyze Weekly includes useful insights written by our team of underpaid MBAs, research on new disruptive technology stocks flying under the radar, and summaries of our recent research. Always 100% free.

Sign up!

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.

Join now